SCHEMBL13171691

SCHEMBL13171691

Cc1ccc(Cn2cc(CC(C)C)cn2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 3/20 0.40
▸ ALOX5AP P20292 1/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ KDR P35968 2/20 0.40
▸ EPHB4 P54760 2/20 0.40
▸ TEK Q02763 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ DUSP3 P51452 1/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19079154 0.87 KCNH2 (0.51) ALOX5APLMNAMAPTL3MBTL1TSHR
SCHEMBL14706819 0.85 L3MBTL1 (0.56) L3MBTL1ADORA2AADORA2BADORA1
SCHEMBL17229326 0.85 KLKB1 (0.46) KLKB1ALOX5APLMNAMAPTL3MBTL1
SCHEMBL2821950 0.80 HSD17B10 (0.43) KLKB1RAB9ANPC1KDREPHB4
SCHEMBL16804397 0.80 CACNA1H (0.43) KLKB1RAB9ANPC1KDREPHB4
SCHEMBL15759268 0.79 KLKB1 (0.51) KLKB1RAB9ANPC1KDREPHB4
SCHEMBL10148103 0.75 MAPT (0.37) LMNAMAPTTSHRKCNH2ALDH1A1
SCHEMBL18858532 0.75 ACHE (0.47) MAPK1
SCHEMBL14706818 0.75 ERCC5 (0.41) RAB9ANPC1MAPTMAPK1SMN1; SMN2
SCHEMBL3593783 0.75 MAPT (0.68) KLKB1RAB9ANPC1KDREPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841455-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors ARRAY BIOPHARMA INC. (US) 2014-09-23 — — US disclosed
US-20120258952-A1 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors ARRAY BIOPHARMA INC. (US) 2012-10-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258952-A1 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors AFF1, FLI1, F3 KLKB1 4275/4885ALOX5AP 4292/4885RAB9A 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback